XL-418

• Description :

  XL-418 is an orally active dual Akt and p70S6K inhibitor with IC50s of 1 nM for Akt1 and 2 nM for p70S6K. XL-418 inhibits the phosphorylation of ribosomal protein S6 and GSK3β. XL-418 can be used for the study of prostate carcinoma and breast cancer[1].

• UNSPSC :

  12352005

• Target :

  Akt; GSK-3; Ribosomal S6 Kinase (RSK)

• Related Pathways :

  MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Smiles :

  O=C(C1=CC(NCCN2CCCC2)=C(C)C(N3CCN(C4=C5C(NN=C5Br)=NC=N4)CC3)=C1)CCC(F)(F)F

• Molecular Formula :

  C26H32BrF3N8O

• Molecular Weight :

  609.48

• References & Citations :

  [1]Rice KD, et al. Pyrazolopyrimidines as dual Akt/p70S6K inhibitors. Bioorg Med Chem Lett. 2012 Apr 15;22 (8) :2693-7.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 1

• Isoform :

  Akt1; GSK-3β; p70S6K

• CAS Number :

  [871343-09-8]